

25 September 2018

# ASX Release NOTICE UNDER SECTION 708A(5)(e) CORPORATIONS ACT 2001 (CTH) and APPENDIX 3B

Byron Energy Limited ("Byron or the Company") (ASX:BYE) today issued 3,766,479 shares to Metgasco Limited ("Metgasco") in consideration for Metgasco converting \$A1,0000,0000 of its remaining \$4,000,000 in convertible notes at \$A0.2655 per share ("Conversion Shares") into shares in the Company.

In order to permit the on-sale of the Conversion Shares without the need for a disclosure document to be prepared under Part 6D.2 of the *Corporations Act 2001* (Cth) ("Corporations Act"), Byron makes the following statements for the purposes of compliance with sections 708A(5)(e) and 708A(6) of the Corporations Act:

- The Conversion Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- b) This notice is being given under paragraph 5(e) of section 708A of the Corporations Act.
- c) As at the date of this notice, Byron has complied with the provisions of Chapter 2M (as they apply to Byron) and section 674 of the Corporations Act.
- d) As at the date of this notice, there is no excluded information (as defined in sections 708A(7) and 708A(8) of the Corporations Act.).

An Appendix 3B in relation to the issue of the Placement Shares is attached.

Yours sincerely,

Nick Filipovic

CFO & Company Secretary

N. Filipperic

61 (3) 8610 6583

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Byron Energy Limited		
ABN		
88 113	436 141	
We (t	he entity) give ASX the followin	g information.
	T 1 – All issues ust complete the relevant sections (attac	th sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	3,766,479 Fully paid ordinary shares
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	Issued for \$Ao.2655 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Conversion of \$A1,000,000, of the \$4,000,000 in convertible notes held by Metgasco Limited, into shares in the Company at 10% discount to 30 day volume weighted average price of the Company's ordinary shares
ба	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	28 November 2017
6с	Number of *securities issued without security holder approval under rule 7.1	None
6d	Number of *securities issued with security holder approval under rule 7.1A	None

<sup>+</sup> See chapter 19 for defined terms.

Number of \*securities issued 3,766,479, approved by shareholders at the бe with security holder approval Company's EGM held on 12 under rule 7.3, or another September 2016 specific security holder approval (specify date of meeting) 6f Number of \*securities issued None under an exception in rule 7.2 If \*securities issued under rule Not Applicable 6g 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the tissue date and both values. Include the source of the VWAP calculation. 6h If \*securities were issued under Not Applicable 7.1A for non-cash consideration, state date on which valuation of consideration was released to **ASX Market Announcements** Calculate the entity's remaining 6i See Annexure 1 - Part 1 and Part 2 issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements \*Issue dates 7 25 September 2018 Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. Number +Class 8 Number and +class of all Fully paid ordinary 688,753,513 \*securities quoted on ASX shares (including the \*securities in section 2 if applicable)

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	<sup>+</sup> Class	
1,950,000	Options exercisable at \$Ao.25 expiry date 5.00 pm (Sydney time) 30 September 2018	
10,000,000	Options exercisable at \$Ao.25 expiry date 5.00 pm (Sydney time) 21 July 2019	
9,500,000	Options exercisable at \$Ao.25 expiry date 5.00 pm (Sydney time) 31 December 2019	
3,000,000	Convertible notes convertible at the election of the note holder (i) between 20 July 2018 and 21 July 2019; or (ii) on the occurrence of a change of control, at a price which is a 10% discount to the 30 day VWAP	
28,350,000	Options exercisable at \$Ao.12 expiry date 5.00 pm (Sydney time) 31 December 2021	
2,000,000	Options exercisable at \$Ao.16 expiry date 5.00 pm (Sydney time) 31 December 2021	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Dividend policy (in the case of a trust, paid ordinary shares

#### Part 2 - Pro rata issue

Is security holder approval required?

Not Applicable

<sup>+</sup> See chapter 19 for defined terms.

12	Is the issue renounceable or non-renounceable?	Not Applicable
13	Ratio in which the *securities will be offered	Not Applicable
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Not Applicable
15	<sup>+</sup> Record date to determine entitlements	Not Applicable
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not Applicable
17	Policy for deciding entitlements in relation to fractions	Not Applicable
18	Names of countries in which the entity has security holders who will not be sent new offer documents	Not Applicable
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	Not Applicable

Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

20	Names of any underwriters	Not Applicable
21	Amount of any underwriting fee or commission	Not Applicable
22	Names of any brokers to the issue	Not Applicable
23	Fee or commission payable to the broker to the issue	Not Applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not Applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not Applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not Applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not Applicable
28	Date rights trading will begin (if applicable)	Not Applicable
29	Date rights trading will end (if applicable)	Not Applicable
30	How do security holders sell their entitlements in full through a broker?	Not Applicable
31	How do security holders sell part of their entitlements through a broker and accept for the balance?	Not Applicable

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	of th	do security holders dispose eir entitlements (except by hrough a broker)?	Not Applicable	
33	<sup>+</sup> Issue	e date	Not Applicable	
		!		
		Quotation of secur complete this section if you are ap		
34	Type (tick	of *securities one)		
(a)		<sup>+</sup> Securities described in Part	1	
(b)		All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entit	ies tl	nat have ticked box 34	(a)	
Addit	ional	securities forming a new	class of securities	
Tick to docume		e you are providing the informat	ion or	
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000		
		1,001 - 5,000 5,001 - 10,000		
		10,001 - 100,000 100,001 and over	·	
37		A copy of any trust deed for	the additional <sup>+</sup> securities	

<sup>+</sup> See chapter 19 for defined terms.

#### Quotation agreement

- <sup>†</sup>Quotation of our additional \*securities is in ASX's absolute discretion. ASX may quote the \*securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

N. Filipperic

Date: 25/09/2018

(Company secretary)

Print name:

Nick Filipovic

 $<sup>\</sup>scriptstyle +$  See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	277,447,162	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval	411,306,351	
<ul> <li>Number of partly paid *ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	0	
"A"	688,753,513	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	103,313,027
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	2,000,000
• Under an exception in rule 7.2	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> </ul> </li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	2,000,000
Step 4: Subtract "C" from ["A" x "Eplacement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	103,313,027
Note: number must be same as shown in Step 2	
Subtract "C"	2,000,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" × 0.15] – "C"	101,313,027
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
"A"	688,753,513		
Note: number must be same as shown in Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
Multiply "A" by 0.10	68,875,351		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A			
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"E"	0		

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	68,875,351	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	68,875,351	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 13

<sup>+</sup> See chapter 19 for defined terms.